Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
11 Outubro 2023 - 9:00AM
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that eight
abstracts highlighting new data from its chronic hepatitis B (CHB)
and chronic hepatitis delta (CHD) clinical programs have been
accepted for presentation at the American Association for the Study
of Liver Diseases (AASLD) The Liver Meeting®, taking place in
Boston, MA, from November 10-14, 2023. These include seven poster
presentations, one of which is a late-breaking poster, and one
late-breaking oral presentation.
“Results from our ongoing studies underscore the
tremendous progress we are making toward addressing the needs of
the millions of people living with chronic hepatitis B and chronic
hepatitis delta,” said Phil Pang, M.D., Ph.D., Vir’s Executive Vice
President, Chief Medical Officer and Interim Head of Research. “We
are eager to present additional data from our multiple ongoing
trials at AASLD, especially the data from two late-breaking
presentations on the potential clinical impact that VIR-3434 and
VIR-2218 could have for both CHB and CHD patients.”
Presentations |
|
|
|
• |
|
Title: VIR-2218 and VIR-3434 therapy is
efficacious in preclinical models of hepatitis delta virus
infection (Poster #1257-C) |
|
|
Session:
Poster Session 1 |
|
|
Date: Friday,
November 10 |
|
|
Time: 12:00
p.m. ET |
|
|
Presenter:
Jiayi Zhou, MBA, Senior Research Associate, Virology at Vir
Biotechnology |
|
|
|
• |
|
Title:
Pharmacokinetics and safety of VIR-2218 monotherapy in adult
cirrhotic participants with moderate hepatic impairment (Poster
#1480-C) |
|
|
Session:
Poster Session 1 |
|
|
Date: Friday,
November 10 |
|
|
Time: 12:00
p.m. ET |
|
|
Presenter:
Sneha V. Gupta, Ph.D., Director, Clinical Pharmacology at Vir
Biotechnology |
|
|
|
• |
|
Title:
Initial evaluation of immune complex binding in a phase 1 safety
and tolerability study of chronic HBV participants given a single
dose of VIR-3434 (Poster #1511-C) |
|
|
Session:
Poster Session 1 |
|
|
Date: Friday,
November 10 |
|
|
Time: 12:00
p.m. ET |
|
|
Presenter:
Rachel Wong, Ph.D., Clinical Immunology Scientist at Vir
Biotechnology |
|
|
|
• |
|
Title:
Assessment of regional impact on the pharmacokinetics of VIR-2218
(BRII-835) in subjects with chronic hepatitis B virus infection
(Poster #1457-C) |
|
|
Session:
Poster Session 1 |
|
|
Date: Friday,
November 10 |
|
|
Time: 12:00
p.m. ET |
|
|
Presenter:
Yali Zhu, Senior Director, Clinical Pharmacology at Brii
Biosciences & Sneha V. Gupta, Ph.D., Director, Clinical
Pharmacology at Vir Biotechnology |
|
|
|
• |
|
Title:
Prevalence of hepatitis B and D virus among a nationally
representative insured population in the United States (Poster
#1379-C) |
|
|
Session:
Poster Session 1 |
|
|
Date: Friday,
November 10 |
|
|
Time: 12:00
p.m. ET |
|
|
Presenter:
Sacha Satram, Ph.D., Director, Health Economics & Outcomes
Research at Vir Biotechnology |
|
|
|
• |
|
Title:
Predictors of treatment initiation among high-risk and grey area
chronic hepatitis B patients in a real-world clinical practice
setting in the United States (Poster #1326-C) |
|
|
Session:
Poster Session 1 |
|
|
Date: Friday,
November 10 |
|
|
Time: 12:00
p.m. ET |
|
|
Presenter:
Sacha Satram, Ph.D., Director, Health Economics & Outcomes
Research at Vir Biotechnology |
|
|
|
Additional details on the late breaking poster and oral
presentations will be shared on November 10, 2023.
About Chronic Hepatitis
BChronic hepatitis B (CHB) infection remains an urgent
global public health challenge associated with significant
morbidity and mortality. Approximately 300 million people around
the world are living with CHB, and approximately 900,000 of them
die from associated complications each year. These patients are
significantly underserved by existing therapies with low functional
cure rates, lifelong daily therapy and/or poor tolerability. Vir is
working to achieve a functional cure for the millions of people
with CHB around the world through its broad and differentiated
portfolio.
About Chronic Hepatitis
DeltaChronic hepatitis delta (CHD) infection occurs as a
simultaneous co-infection or super-infection with chronic hepatitis
B. An estimated 12 million people globally are infected with CHD,
representing approximately 5% of those infected with CHB. CHB-CHD
co-infection is considered the most severe form of chronic viral
hepatitis due to more rapid progression toward hepatocellular
carcinoma and liver-related death.
About VIR-2218 VIR-2218
(BRII-835) is an investigational subcutaneously administered
hepatitis B virus-targeting small interfering ribonucleic acid
(siRNA) that Vir believes has the potential to stimulate an immune
response and have direct antiviral activity against hepatitis B
virus and hepatitis delta virus. It is the first siRNA in the
clinic to include Enhanced Stabilization Chemistry Plus (ESC+)
technology to enhance stability and minimize off-target activity,
which potentially could result in an increased therapeutic index.
VIR-2218 is the first asset in the Company’s collaboration with
Alnylam Pharmaceuticals, Inc. to enter clinical trials.
About VIR-3434VIR-3434
(BRII-877) is an investigational subcutaneously administered
antibody designed to block entry of hepatitis B and hepatitis delta
viruses into hepatocytes and to reduce the level of virions and
subviral particles in the blood. VIR-3434, which incorporates
Xencor’s Xtend™ and other Fc technologies, has been engineered to
potentially function as a T cell vaccine against hepatitis B virus
and hepatitis delta virus, as well as to have an extended
half-life. VIR-3434 was identified using Vir’s proprietary
monoclonal antibody discovery platform.
About Vir BiotechnologyVir
Biotechnology, Inc. is an immunology company focused on combining
cutting-edge technologies to treat and prevent infectious diseases
and other serious conditions. Vir has assembled two technology
platforms that are designed to stimulate and enhance the immune
system by exploiting critical observations of natural immune
processes. Its current clinical development pipeline consists of
product candidates targeting hepatitis B and hepatitis delta
viruses, influenza A and B, human immunodeficiency virus and
COVID-19. Vir has several preclinical candidates in its pipeline,
including those targeting RSV/MPV and HPV. Vir routinely posts
information that may be important to investors on its website.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Words such as “may,” “will,” “plan,” “potential,” “aim,” “expect,”
“anticipate,” “promising” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Vir’s expectations
and assumptions as of the date of this press release.
Forward-looking statements contained in this press release include,
but are not limited to, statements regarding Vir’s strategy and
plans, the potential clinical effects of VIR-3434 and VIR-2218, the
potential benefits, safety and efficacy of VIR-3434 and VIR-2218,
data from Vir’s multiple ongoing trials evaluating VIR-3434 and
VIR-2218, Vir’s plans and expectations for its HBV and HDV
portfolios, and risks and uncertainties associated with drug
development and commercialization. Many factors may cause
differences between current expectations and actual results,
including unexpected safety or efficacy data or results observed
during clinical trials or in data readouts; the occurrence of
adverse safety events; risks of unexpected costs, delays or other
unexpected hurdles; difficulties in collaborating with other
companies; successful development and/or commercialization of
alternative product candidates by Vir’s competitors; changes in
expected or existing competition; delays in or disruptions to Vir’s
business or clinical trials due to the COVID-19 pandemic,
geopolitical changes (including the war in Ukraine) or other
external factors; and unexpected litigation or other disputes. Drug
development and commercialization involve a high degree of risk,
and only a small number of research and development programs result
in commercialization of a product. Results in early-stage clinical
trials may not be indicative of full results or results from later
stage or larger scale clinical trials and do not ensure regulatory
approval. You should not place undue reliance on these statements,
or the scientific data presented. Other factors that may cause
actual results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
Vir’s filings with the U.S. Securities and Exchange Commission,
including the section titled “Risk Factors” contained therein.
Except as required by law, Vir assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
Contacts:
Media
Carly Scaduto
Senior Director, Media Relations
cscaduto@vir.bio
+1-314-368-5189
Investors
Sasha Damouni Ellis
Executive Vice President, Chief Corporate Affairs Officer
sdamouni@vir.bio
Vir Biotechnology (NASDAQ:VIR)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Vir Biotechnology (NASDAQ:VIR)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024